For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
After falling short in a label-extension trial Johnson & Johnson still sees a path forward for its blood thinner in preventing venous thromboembolism.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.